Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by KayakerBCon Mar 30, 2021 9:23am
160 Views
Post# 32904919

RE:Chirpers

RE:ChirpersThere -you are are all busy chirping a lot these days. We get it. If Bioasis continues to idle along at 35/40 cents or less you are right and JD, Chrispi, Kayaker and a few others are wrong.

Sorry, bro, not me.  I think management is doing the best they can with the (lack of) cash they have, but for years I've been saying....

"....This stock isn't moving up until we get more deals, milestone payments, and most importantly -- a clinical trial...."

and I correctly predicted that the Q1, 2022 start of 001 Phase 1 would be pushed out....

"I don't think the current pipeline timeline for Phase I XB3-001 starting Q1, 2022 will happen.  I suspect in the next presentation or two, we'll see the timeline for 001 get bumped out 6+ months."
<< Previous
Bullboard Posts
Next >>